Spots Global Cancer Trial Database for Study on TIL for the Treatment of r/r Gastrointestinal Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study on TIL for the Treatment of r/r Gastrointestinal Tumors
Official Title: A Clinical Safety and Efficacy Study on TIL for the Treatment of r/r Gastrointestinal Tumors
Study ID: NCT04960072
Conditions
Interventions
Study Description
Brief Summary: This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gastrointestinal tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Tenth People's Hospital, Shanghai, , China
Contact Details
Name: Qing Xu
Affiliation: Shanghai 10th People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
